Nuclear Medicine/ Radiopharmaceuticals Market worth $5.26 billion by 2023

According to the new market research report “North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Don’t miss out on business opportunities in “Radiopharmaceuticals Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417
Early buyers will receive 10% customization on reports.

Browse and in-depth TOC on “Radiopharmaceuticals Market”
92 - Tables

60 - Figures

180 - Pages

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

On the basis of country, the market is divided into U.S. and Canada. In 2015, U.S. accounts for the largest share of the North American nuclear medicine/radiopharmaceuticals market, followed by Canada. The major factors driving market growth in the U.S. include the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer Healthcare (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).

Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=417